Navigation Links
Malaria Vaccine Developer Sanaria Inc. and the University of Maryland Biotechnology Institute Awarded Collaborative, Multi-Year, US $600,000 NIH Phase I Small Business Innovation Research Grant
Date:7/29/2008

ROCKVILLE, Md., July 29 /PRNewswire-USNewswire/ -- Sanaria Inc., a privately held company in Rockville, Maryland, and the University of Maryland Biotechnology Institute (UMBI) announced the receipt of a multi-year Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. The grant will support research and development efforts to genetically engineer mosquitoes that can enhance Sanaria's whole-parasite malaria vaccine production process. Malaria vaccine development is a major humanitarian objective. Malaria causes more than 500 million clinical cases and one million deaths each year. The majority of victims are African children. Tens of thousands of travelers contract malaria annually. During the past 150 years, whenever U.S. military forces have been deployed to areas with significant malaria transmission, they have suffered more casualties from malaria than from hostile fire.

According to Dr. David O'Brochta, Ph.D., a Principal Investigator on the grant and Director of the Insect Transformation Facility at UMBI, "The partnership between Sanaria and UMBI supported by this SBIR grant is an ideal example of public-private partnership in the development of groundbreaking technology. It presents an extraordinary opportunity to exploit the capabilities of our Insect Transformation Facility in pursuit of a goal of enormous biomedical importance." Stephen L. Hoffman, M.D., CEO of Sanaria Inc., notes, "We have now competed successfully for over US $12 million in peer-reviewed NIAID SBIR grants. The SBIR grants and our other grants are providing more than US $50 million to Sanaria. These grants are critical to the success of our Malaria Vaccine development efforts which are aimed at reducing the enormous morbidity and mortality caused by malaria throughout the world, but especially in infants and children in sub-Saharan Africa. This collaboration with the UMBI provides an excellent opportunity to exploit state-of-the-art mosquito transformation technology in pursuit of our goal of producing very high numbers of malaria parasites in mosquitoes."

About Sanaria Inc.

Sanaria Inc. was founded in 2003. The company's mission is to develop and commercialize a malaria sporozoite vaccine against Plasmodium falciparum, the parasite responsible for more than 95 percent of malaria-associated severe illness and death world-wide, and the malaria parasite for which there is the most significant drug resistance. Sanaria plans to begin the first human trials of its Malaria Vaccine in 2009. For more information, see http://www.sanaria.com. Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risks and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements relate to the use of funds to date to complete manufacturing the vaccine, and ability to raise sufficient funding for clinical studies. Such risks and uncertainties include, but are not limited to, the Company's ability to raise funds on reasonable terms, the regulatory approval process, competitive products, and maintenance of its patent portfolio, among others.

About UMBI and the Insect Transformation Facility

With research centers in Baltimore, Rockville, and College Park, UMBI, the University of Maryland Biotechnology Institute, is the newest of 13 institutions forming the University System of Maryland. UMBI has more than 60 ladder-ranked faculty and a mandate to advance the biotechnology economy while preparing a well-equipped workforce. Celebrating more than 20 years of service to Maryland and the world, UMBI is led by microbiologist and former biotechnology executive Dr. Jennie C. Hunter-Cevera. For more information visit http://www.umbi.org. UMBI's Insect Transformation Facility (ITF) provides a variety of services related to the creation of tranformant insects including embryo microinjections, tranformant strain production and characterization, facility use, consultation, and training. The ITF has skilled insect transformation professionals with experience and expertise in a wide variety of insects of agricultural and biomedical significance. The ITF can accommodate a variety of working relationships with researchers including collaborations, subcontracts, and fee-for-services. For more information, visit http://umbi.org/carb/core-facilities/insect-transformation/facility.php or call 240-314-6331.


'/>"/>
SOURCE Sanaria Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. U of M researchers find cerebral malaria may be a major cause of brain injury in African children
2. Senate Passes Landmark AIDS, TB and Malaria Bill, Says Global AIDS Alliance
3. Malaria prevention reduces anemia and improves educational potential in Kenyan schoolchildren
4. Discovery of key malaria proteins could mean sticky end for parasite
5. World Vision Launches Initiative to Combat Malaria
6. Maternal malaria researcher wins prestigious international prize
7. Researchers block transmission of malaria in animal tests
8. New MRI to debut in African nation of Malawi; will save lives, advance malaria research
9. Viacom to Receive Leadership Award for Business Excellence from The Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria for Its 25 Years of Work on HIV/AIDS Education and Advocacy
10. Protein plays key role in transmitting deadly malaria parasite
11. UNICEF: Every Second Can Make a Difference to Myanmars Children; 20% Already Suffering from Diarrhea, Malaria reported
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 2016 , ... The U.S. Food and Drug Administration today ... submit their products through an arduous federal approval process. The rules, which treat ... market since February 15, 2007. That would essentially ban 99 percent of all ...
(Date:5/5/2016)... ... , ... This weekend, from Friday, May 6 - Sunday, May 8, fifteen elite athletes from ... Team Semper Fi Mountain Bike Camp, hosted in conjunction with WTB and ... and Jason Moeschler, who’ll share pro tips with the injured veterans as they rip down ...
(Date:5/5/2016)... ... May 05, 2016 , ... LELO has discovered many people ... fans reach out via email, social media and on the Volonté blog seeking advice ... way I masturbate ‘normal’ or ‘correct’?” , While some methods are more common than ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... in all U.S. states and certain Canadian provinces is now available from the ... Research Institute (WCRI). , The report, Workers’ Compensation Laws as of ...
(Date:5/5/2016)... ... 05, 2016 , ... Long Island’s fastest growing comprehensive eye care provider, ... surgeon, Kathleen Van Valkenburg, MD as part of their ongoing effort to increase ophthalmic ... and managing partner of North Shore Eye Care. , “We are extremely proud ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 Research and ... Actinic Keratosis Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Landscape Highlights 2016, provides comprehensive insights into ... Actinic Keratosis market valuations and forecast, Actinic ...
(Date:5/3/2016)... 4, 2016 Global Insulin ... profiling 09 key companies and supported with 272 ... in-depth study on the current state of the ... the industry including definitions, classifications, applications and industry ... provided for the international market including development history, ...
(Date:5/3/2016)... Research and Markets has announced the addition ... Outlook 2020" report to their offering. ... has improved significantly in past years due to which ... years. Many cancer drugs have been developed by utilization ... expected to be developed with its help. They are ...
Breaking Medicine Technology: